Year archive

Xbrane Biopharma — 2024 filings

All 69 regulatory filings released by Xbrane Biopharma (XBRANE) in 2024, sourced directly from the official regulator.

69 Filings

2024 Period

2024 filings (69)

Filing	Released	Lang
XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA Regulatory Filings	2024-12-31	English
XBRANE LÄMNAR in BLA FÖR RANIBIZUMAB BIOSIMILAR KANDIDAT TILL FDA Report Publication Announcement	2024-12-31	Swedish
Xbrane announces outcome of exercise of warrants of series TO1 Capital/Financing Update	2024-12-18	English
Xbrane offentliggör utfall av utnyttjande av teckningsoptioner av serie TO1 Capital/Financing Update	2024-12-18	Swedish
XBRANE BIOPHARMAS HUVUDÄGARE SYSTEMATIC GROUP GER KORTSIKTIGT LÅN PÅ 20 MSEK TILL BOLAGET Capital/Financing Update	2024-12-02	Swedish
XBRANE BIOPHARMA'S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN OF SEK 20 M TO THE COMPANY Capital/Financing Update	2024-12-02	English
Xbrane AB (publ) informerar idag att bolagets CFO, Anette Lindqvist, har meddelat sin avsikt att gå i pension och kommer under våren 2025 lämna sitt uppdrag. Board/Management Information	2024-11-26	Swedish
Xbrane AB (publ) today announces that the company's CFO, Anette Lindqvist, has announced her intention to retire and will leave her position during the spring of 2025. Board/Management Information	2024-11-26	English
XBRANE BIOPHARMA ANNOUNCES NOMINATION COMMITTEE CHANGES Board/Management Information	2024-11-21	English
XBRANE BIOPHARMA MEDDELAR FÖRÄNDRING AV VALBEREDNING Board/Management Information	2024-11-21	Swedish
Xbrane och Intas ingår ett globalt licens- och samutvecklingsavtal för Xbranes Nivolumab biosimilar med referens Opdivo® Regulatory Filings	2024-11-19	Swedish
Xbrane and Intas enter into a Global Licensing agreement to jointly develop Nivolumab biosimilar referencing Opdivo® M&A Activity	2024-11-19	English
XBRANE BIOPHARMA PRESENTS NOMINATION COMMITTEE Board/Management Information	2024-10-31	English
XBRANE BIOPHARMA PRESENTERAR VALBEREDNING AGM Information	2024-10-31	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report 9M 2024	2024-10-24	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report 9M 2024	2024-10-24	English
XBRANE PROVIDES UPDATE ON THE ONGOING OUT-LICENSING OF XDIVANE™ (NIVOLUMAB BIOSIMILAR CANDIDATE) AND XB003 (CIMZIA® BIOSIMILAR CANDIDATE) AND ITS FINANCIAL POSITION Regulatory Filings	2024-10-21	English
XBRANE UPPDATERAR avseende DEN PÅGÅENDE UTLICIENSIERINGEN AV XDIVANE™ (NIVOLUMAB BIOSIMILARKANDIDAT) OCH XB003 (CIMZIA® BIOSIMILARKANDIDAT) samt BOLAGETS FINANSIELLA STÄLLNING Regulatory Filings	2024-10-21	Swedish
Xbrane provides update from Scientific Advice with US FDA on Xdivane™ (Opdivo® biosimilar candidate) Report Publication Announcement	2024-09-27	English
Xbrane uppdaterar från vetenskapligt rådgivande möte med US FDA angående Xdivane™ (Opdivo® biosimilarkandidat) Report Publication Announcement	2024-09-27	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report H1 2024	2024-08-28	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report H1 2024	2024-08-28	English
Xbrane provides update on the ongoing out-licensing of Xdivane™ (nivolumab biosimilar candidate) and XB003 (Cimzia® biosimilar candidate) and its financial position Management Reports	2024-08-12	English
Xbrane uppdaterar om pågående utlicensiering av Xdivane™ (Opdivo® biosimilarkandidat) och XB003 (Cimzia® biosimilarkandidat) och finansiell ställning Regulatory Filings	2024-08-12	Swedish
Xbrane to regain full rights to BIIB801, a proposed biosimilar referencing CIMZIA® M&A Activity	2024-08-01	English
Xbrane återfår fullständiga rättigheter till BIIB801, en föreslagen biosimilar till CIMZIA® Regulatory Filings	2024-08-01	Swedish
Xbrane Provides update on timing of re-submission of BLA for ranibizumab biosimilar candidate Report Publication Announcement	2024-07-08	English
Xbrane uppdaterar om tidpunkt för återinskick av BLA för ranibizumab biosimilar kandidat Regulatory Filings	2024-07-08	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report Q1 2024	2024-05-16	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report Q1 2024	2024-05-16	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-05-10	English
Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US Regulatory Filings	2024-05-10	English
Xbrane och STADA ingår partnerskap med Valorum Biologics för att kommersialisera biosimilarkandidaten för ranibizumab i USA. Regulatory Filings	2024-05-10	Swedish
Announcement from Xbrane Biopharma's annual general meeting AGM Information	2024-05-02	English
Kommuniké från årsstämman i Xbrane Biopharma AGM Information	2024-05-02	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-04-24	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-04-23	English
Xbrane provides regulatory update on FDA review of its ranibizumab biosimilar candidate Regulatory Filings	2024-04-21	English
Xbrane uppdaterar kring FDAs granskning av ranibizumab biosimilarkandidat Regulatory Filings	2024-04-21	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-04-03	English
Notice of annual general meeting in Xbrane Biopharma AB AGM Information	2024-04-02	English
Kallelse till årsstämma i Xbrane Biopharma AB AGM Information	2024-04-02	Swedish
Change of number of shares and votes in Xbrane Declaration of Voting Results & Voting Rights Announcements	2024-04-01	English
Förändrat antal aktier och röster i Xbrane Declaration of Voting Results & Voting Rights Announcements	2024-04-01	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-03-28	English
Annual Report 2023 Annual Report FY 2023	2024-03-27	Swedish
Annual Report 2023 Annual Report FY 2023	2024-03-27	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-03-26	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-03-26	Swedish
Xbrane resolves on a directed issue of shares to guarantors in connection with the completed rights issue Share Issue/Capital Change	2024-03-19	English
Xbrane beslutar om en riktad emission av aktier till garanter i samband med den genomförda företrädesemissionen Share Issue/Capital Change	2024-03-19	Swedish
Xbrane announces the outcome of the rights issue Capital/Financing Update	2024-03-14	English
Xbrane offentliggör utfallet i företrädesemissionen Capital/Financing Update	2024-03-14	Swedish
Xbrane has received additional subscription undertakings corresponding to approximately SEK 18.1 million in the Company's rights issue Capital/Financing Update	2024-03-04	English
Xbrane har erhållit ytterligare teckningsåtaganden motsvarande cirka 18,1 MSEK i bolagets företrädesemission Share Issue/Capital Change	2024-03-04	Swedish
Xbrane publishes prospectus in connection with the company’s partially guaranteed rights issue of approximately SEK 343 million Share Issue/Capital Change	2024-02-27	English
Xbrane publicerar prospekt i samband med bolagets partiellt garanterade företrädesemission om cirka 343 MSEK Capital/Financing Update	2024-02-27	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report FY 2023	2024-02-26	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report Q4 2023	2024-02-26	English
Rättelse: Kommuniké från extra bolagsstämma i Xbrane Biopharma AB AGM Information	2024-02-22	Swedish
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB Declaration of Voting Results & Voting Rights Announcements	2024-02-22	Swedish
Announcement from Extra General Meeting in Xbrane Biopharma AB Declaration of Voting Results & Voting Rights Announcements	2024-02-22	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-02-16	English
Declaration of Voting Results & Voting Rights Announcements 2024 Declaration of Voting Results & Voting Rights Announcements	2024-02-15	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-02-14	English
Notice of Extra General Meeting in Xbrane Biopharma AB AGM Information	2024-01-22	English
Kallelse till extra bolagsstämma i Xbrane Biopharma AB AGM Information	2024-01-22	Swedish
Xbrane announces a rights issue of units of approximately SEK 343 million Capital/Financing Update	2024-01-22	English
Xbrane offentliggör en företrädesemission av units om cirka 343 MSEK Capital/Financing Update	2024-01-22	Swedish

Filings by year

2026 16 filings
2025 64 filings
2024 69 filings
2023 63 filings
2022 41 filings
2021 39 filings
2020 62 filings
2019 5 filings